Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
via Google News
The Latest on: Type 1 diabetes
- Penny Marshall Died from Complications from Diabetes—Here's How That Happens on December 19, 2018 at 11:20 am
Marshall spoke about other health problems over the years—including lung and brain cancer diagnoses in 2009—but not about diabetes. It’s unclear how long she lived with the condition, or whether she h... […]
- Researchers zero in on potential therapeutic target for diabetes, associated diseases on December 19, 2018 at 10:35 am
"A high glucagon level is present in both Type 1 and Type 2 diabetes, and Foxo1 plays a key role in the fundamental mechanism leading to excess liver gluconeogenesis and resulting in diabetic hypergly... […]
- Amputatee, Colin Rattray, who has type 2 diabetes walks with prosthetic leg on December 19, 2018 at 9:32 am
... walks with prosthetic leg Colin Rattray who has type 2 diabetes who had lower leg amputated walks with prosthetic leg ©News Group Newspapers Limited in England No. 679215 Registered office: 1 Lond... […]
- Alterations detected in brain connectivity in patients with type 1 diabetes on December 19, 2018 at 6:37 am
Barcelona researchers of the of the Institute of Neurosciences and the Institute of Complex Systems (UBICS) of the University of Barcelona. Credit: Universidad de Barcelona Patients with type 1 ... […]
- Kidney failure is increasing in Australians under 50 with type 2 diabetes, study finds on December 19, 2018 at 6:34 am
A study of more than 1.3 million Australians with diabetes has found that kidney failure is increasing in people with type 2 diabetes aged under 50 years, leading to reduced quality of life and placin... […]
- Kidney failure on the rise in Australians under 50 with type 2 diabetes on December 19, 2018 at 5:49 am
A study of more than 1.3 million Australians with diabetes has found that kidney failure is increasing in people with type 2 diabetes aged under 50 years, leading to reduced quality of life and ... […]
- Substance use higher among adults with type 1 diabetes vs. general population on December 19, 2018 at 4:09 am
Use of substances such as alcohol, opioids and sedative medications may be higher among adults with type 1 diabetes compared with the overall U.S. population, according to findings published in The Di... […]
- Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes on December 19, 2018 at 2:00 am
Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors. The Phase 1 trial wil... […]
- Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises on December 18, 2018 at 10:15 pm
... to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the European ... […]
via Bing News